Wrinkle Clinical Trial
Official title:
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
Status | Recruiting |
Enrollment | 85 |
Est. completion date | May 31, 2029 |
Est. primary completion date | May 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Male or female in good general health, as determined by the investigator, aged =18 and =75 at the time of consent (only females for Cohort 4) 2. Regions of suitable skin to be selected as Target Area(s), as determined by a physical examination conducted by the investigator during the initial visit: - Cohort 1 - region of healthy buttock skin - Cohort 1a - bilaterally symmetric regions of healthy buttock skin at least 6 cm apart - Cohort 2 - bilaterally symmetric regions of moderate to severe fine lines and skin roughness (score of 2 or 3), as determined by investigator using the 5-point FLS and SRS on the cheeks above and below the zygomatic arch - Cohort 2 Extension- A subject who received a high dose regimen of KB301 to Target Areas below the zygomatic arch - Treatment group- Unilateral region of the cheek below the zygomatic arch, which was randomized to received placebo under Cohort 2, that per investigator assessment and consultation with the sponsor at Visit 1, is determined to be uneven as compared to the Target Area which received KB301 - Observational group - Bilateral region of the cheeks below the zygomatic arch which were randomized to receive high dose 301 under Cohort 2 that show durability of KB301 to at least one of the two Target Areas - Cohort 3- Lateral canthal lines of mild to moderate severity at rest, per the Investigator's clinical assessment - Cohort 4- Dynamic décolleté wrinkles and /or pigmentation 3. A Fitzpatrick skin phototype score of I-IV 4. A negative pregnancy test at the Study Day 0 Visit for subjects of child-bearing potential and 5. Signed and dated informed consent and willingness to attend all study visits and complete all procedures required by this protocol. Exclusion Criteria: 1. Any transient or chronic skin condition, disorder, or infection within 20 cm of the Target Areas at Day 0 that, in the opinion of the investigator, may confound study results 2. History of laser treatment or chemical peels to the Target Areas within six (6) months of the Study Day 0 Visit 3. History of surgical procedures to Target Areas, including removal of benign or malignant skin cancers that, in the opinion of the investigator, may confound study results 4. Administration of a cosmetic and/or clinical research investigational agent, at the location of the Target Areas within 6 months of the Study Day 0 Visit, that, in the opinion of the investigator, may confound study results 5. Scars, tattoos or tanned skin (defined as skin that is tanned from sun exposure or an applied skin color such as a spray tan) within the Target Area 6. Any condition (including a history or current evidence of substance abuse or dependence) that, in the investigator's opinion, would impact subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of the Investigational Product 7. Women who are pregnant or nursing 8. Subject who is unwilling to comply with contraception requirements per-protocol 9. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol, in the opinion of the investigator. 10. Previously treated with KB301 under Cohorts 2, 2-extension, 3a, or 3b (Cohort 3c only) |
Country | Name | City | State |
---|---|---|---|
United States | Skin and Cancer Associates, LLP. D/B/A Center for Clinical and Cosmetic Research | Aventura | Florida |
United States | Aesthetx | Campbell | California |
United States | Steve Yoelin, MD Medical Associates, Inc. | Newport Beach | California |
United States | Mission Dermatology | Rancho Santa Margarita | California |
Lead Sponsor | Collaborator |
---|---|
Krystal Biotech, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of the safety profile of KB301 by recording adverse events using MedDRA System Organ Class and Preferred Term and collection of other clinical study procedures. | The primary outcome will look at the safety and tolerability of KB301 through the collection and quantification of adverse events, physical examinations, vital signs and clinical laboratory tests. | 4 months | |
Secondary | Evaluation of COL3A1 transgene expression 2-days post-dose. | The secondary outcome measure in Cohorts 1 and 1a will compare a KB301 injection site biopsy, to an area of untreated healthy buttock skin biopsy (at least 6 cm away from the sites of KB301 injection), via qRT-PCR analysis. | 12 months | |
Secondary | Assessment of skin roughness as compared to baseline, using the Skin Roughness Scale (SRS). | The secondary outcome measure in Cohort 2 will look at the mean change in the assessment of skin roughness as compared to baseline, using the Skin Roughness Scale (SRS). The SRS ranges from no fine lines (0) to extreme fine lines (4). A third-party independent blinded evaluator will perform the evaluations. | 65 Days | |
Secondary | Assessment of fine line improvement as compared to baseline, using the Fine Lines Scale (FLS). | The secondary outcome measure in Cohort 2, will look at the mean change in the assessment of fine lines as compared to baseline, using the Fine Lines Scale (FLS). The FLS ranges from no texture (0) to diffuse texture (4). A third-party independent blinded evaluator will perform the evaluations. | 65 Days | |
Secondary | Subject assessment of aesthetic improvement over baseline, using the Subject Satisfaction Scale (SSS). | The secondary outcome measure in Cohort 2, will look at the mean change in Subject's Satisfaction with the treatment per target area, as compared to baseline, using the Subject Satisfaction Scale (SSS), which is scored on a scale from 0-4, with 0 indicating not satisfied and 4 indicating excellent. | 65 Days | |
Secondary | Assessment of skin fold thickness improvement over baseline, using a Caliper. | The secondary outcome measure in Cohort 2, will look at the mean change in skinfold thickness of the non-facial target areas above the knee, using a Caliper to measure, as compared to baseline. | 65 Days | |
Secondary | Subject assessment of aesthetic improvement over baseline, using the Subject Satisfaction Scale (SSS). | The secondary outcome measure in Cohort 2 Extension, will look at the mean change in Subject's Satisfaction with the treatment per target area, as compared to baseline, using the Subject Satisfaction Scale (SSS), which is scored on a scale from 0-4, with 0 indicating not satisfied and 4 indicating excellent. | 3 Months | |
Secondary | Investigator assessment of durability of high dose KB301, as compared to baseline. | The secondary outcome measure in Cohort 2 Extension, will look at the durability of high dose KB301, as compared to baseline through an Investigator assessment. | 3 Months | |
Secondary | Investigator assessment of global aesthetic improvement, as compared to baseline. | The secondary outcome measure in Cohort 3 and Cohort 4 will look at the mean change in global aesthetic improvement, which is scored on a 5-point scale, ranging from much improved (2) to much worse (-2). | 4 Months | |
Secondary | Subject assessment of global aesthetic improvement, as compared to baseline. | The secondary outcome measure in Cohort 3 and Cohort 4 will look at the mean change in global aesthetic improvement, which is scored on a 5-point scale, ranging from much improved (2) to much worse (-2). | 4 Months | |
Secondary | Subject treatment satisfaction as compared to baseline, using the Subject Satisfaction Questionnaire (SSQ). | The secondary outcome measure in Cohort 3 and Cohort 4 will look at mean change in subject treatment satisfaction over baseline, using a 5-point Subject Satisfaction Questionnaire, ranging from very satisfied (2) to very dissatisfied (-2). | 4 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05098912 -
Comparing Polydioxanone Thread Embedding Acupuncture and Manual Acupuncture for Nasolabial Fold Reduction
|
N/A | |
Completed |
NCT05271136 -
A Clinical Study to Evaluate the Efficacy of an Anti-Aging Serum
|
N/A | |
Completed |
NCT05096247 -
Post Market Study To Collect Efficacy Data For The Treatment Of Wrinkles With A Radiofrequency Device
|
N/A | |
Completed |
NCT05097157 -
Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions
|
N/A | |
Completed |
NCT04128046 -
The Effect of Platelet-rich Fibrin Matrix on Skin Rejuvenation
|
N/A | |
Active, not recruiting |
NCT04727099 -
Clinical Evaluation to Demonstrate the Safety and Performance of the Candela PicoWay System™
|
N/A | |
Active, not recruiting |
NCT06140628 -
A 28-day Clinical Study on Facial Skin Rejuvenation
|
N/A | |
Not yet recruiting |
NCT05524779 -
BTL-785F Device for Non-invasive Reduction of Wrinkles and Overall Facial Improvement
|
N/A | |
Completed |
NCT05514782 -
A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum
|
N/A | |
Completed |
NCT06123572 -
A Clinical Study to Assess the Safety and Effectiveness of Anti-Ageing and Skin Brightening Gel
|
N/A | |
Completed |
NCT04911374 -
An Open-Label Clinical Study to Evaluate the Efficacy of a Face Cream and Eye Cream
|
N/A | |
Recruiting |
NCT04989361 -
Soluble Hyaluronic Acid Microneedle VS. Non-ablative Fractional Laser on Infraorbital Wrinkles.
|
N/A | |
Recruiting |
NCT06074276 -
The Effects of Almond on Facial Skin Collagen and Wrinkles
|
N/A | |
Recruiting |
NCT06202274 -
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
|
N/A | |
Completed |
NCT06366503 -
Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation
|
N/A | |
Active, not recruiting |
NCT06219278 -
A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles
|
N/A | |
Active, not recruiting |
NCT06192550 -
Functional Usability and Feasibility Testing of the Profound Matrix™ System
|
N/A | |
Completed |
NCT04650620 -
Study to Evaluate the Performance and Safety of the Medical Device Plenhyage®
|
N/A | |
Completed |
NCT03729700 -
The Effect of Almonds on Facial Aesthetics and Modulation of the Microbiome and Lipidome
|
N/A | |
Completed |
NCT05102617 -
Post Market Usability Evaluation Of The PicoSure Pro Device
|
N/A |